BRCA突变乳腺癌的临床研究进展

Progress of clinical research on breast cancer with BRCA mutation

摘要: BRCA1和BRCA2是遗传性乳腺癌的主要相关基因。随着PARP抑制剂的临床应用，BRCA突变也成为了乳腺癌的治疗靶点。在BRCA突变乳腺癌患者中，talazoparib、veliparib、奥拉帕利、尼拉帕利等PARP抑制剂已被广泛应用在新辅助治疗、辅助治疗和晚期治疗各个阶段，治疗模式有PARP抑制剂单药、联合化疗、联合免疫治疗等多种方式。本文就BRCA突变乳腺癌的临床研究进展进行综述。

Abstract: BRCA1 and BRCA2 are the main inherited breast cancer-related genes. With the clinical application of PARP inhibitors, BRCA mutation has become a therapeutic target for breast cancer. Currently, talazoparib, veliparib, olaparib, niraparib, and other PARP inhibitors are widely used in neoadjuvant therapy, adjuvant therapy, and advanced treatment for breast cancer patients with BRCA mutation. The treatment modes include single drug, combined chemotherapy, combined immunotherapy, etc. In this article, we review the progress of clinical research on breast cancer with BRCA mutation.